ã¡ãã£ã¢èšäº
ã¯ã¯ãã³ãéžæå¯èœã«ãæ¥çš®äŒå Žããšçš®é¡åãâå°æè£äœå®
ããºãææ°ããŒã¯ 1,828
twitterã³ã¡ã³ã 485ä»¶äž 101ïœ200件
ç§ã¯ãã¶ãåŸ
ããã«æ©ãåãããããšãã«è¡ããŸãã
ãã®ãéžæå¯èœãã£ãŠãã€ãæªãäºæããããªãããã
ãã®ãéžæå¯èœãã£ãŠãã€ãæªãäºæããããªãããã
ããã£ãã
ãããŠãŒãã倧混乱ããããã
ãŸãããã
ããã¯æ¯éãã£ãŠæ¬²ããããŸãéžã¹ããããªç¶æ³åœåããªããã©ã
èªæ²»äœã«äŒããäžã§ïŒçºèšããŠããã®ããªããã¯ã¯ãã³ã®äººæ°ã«å·®ãåºããïŒå¿æ®ºãããšæãããïŒ
æ°åã³ããã¯ã¯ãã³ãéžæå¯èœã«ã æ¥çš®äŒå Žããšçš®é¡åãâå°æ倧è£è£äœå®ãä»æã®æ¥æå ±éPRIMEã§
æ··ä¹±ã®å
ãå¢ãããªãâŠ
å瀟ã®ã¯ã¯ãã³ãæã£ãŠããããã«æ¹è©ããã¯ã¯ãã³ãœã ãªãšãçŸãããããã®ããªïŒ
äžéãæ¥çš®ãçµããã®ã¯ããã«å
ã«ãªããããå人ã®éžæãšããããšã«ããã°ãã©ãã«ãé¿ãããããšããããšãªãã§ããããã / âæ°åã³ãã
æ¹å€ããŠã人ãå€ããã©ãã¯ã±ããããç©ãå°ããããããåŸ
ã€ã®ã¯èªå·±è²¬ä»»ã ãã©ãèªç±ã«éžã¹ãã®ã¯ããã£ãã
ãã¡ã€ã¶ãŒãã¢ãã«ããã¢ã¹ãã©ãŒãã«ãäžè¬åããšããŠäŸçµŠãããäºå®ã
詳ããã¯ãã¡ãã®èšäºãåç
§ãã ããâª
ãŸã ã¯ã¯ãã³ç¢ºä¿ãæªç¢ºå®ãªã®ã«ãã¡ãã£ãšå
èµ°ããããããªãã§ããïŒ
è€æ°ã®æ¥çš®äŒå Žã§åããããšãåæãšããŠãã
éå£æ¥çš®äŒå ŽãïŒã€æºåããã®ã倧å€ãªã®ã«
ãŸãèšãã ããªãç°¡åã§ããã
è€æ°ã®æ¥çš®äŒå Žã§åããããšãåæãšããŠãã
éå£æ¥çš®äŒå ŽãïŒã€æºåããã®ã倧å€ãªã®ã«
ãŸãèšãã ããªãç°¡åã§ããã
ã¢ãã«ãããããªã
ãäŒå Žãéžã¹ã°æã€ã¯ã¯ãã³ãéžã¶ããšãã§ãã~æ¿åºã¯1äŒå Žã§äœ¿çšããã¯ã¯ãã³ã¯1çš®é¡ãšããæ¹é~è±è£œè¬å€§æã¢ã¹ãã©ãŒãã«ãšç±³ãã€ãªå»è¬åäŒæ¥ã¢ãã«ããããã¢ãã¢ã§ã®ã¬ãå§èªäºã®èã«èŠæã / âæ°åã³ãã
ã©ããéžã¹ã°ããã®ã
çŸåšäºå®ãããŠããã®ã¯2çš®é¡ã ããå瀟ã®éçºç¶æ³ããå€æããŠãä»åŸäœ¿çšã§ããã¯ã¯ãã³ã®çš®é¡ãå¢ããããšãäºæ³ãããã被æ¥çš®è
ãèªç±ã«éžæã§ããã®ã¯å€§äºãªããšã§ããã®å€æã®ããã«å¯èœãªéãã®äºåã®æ
å ±æäŸ(ã¯ã¯ãã³ã®ã¿ã€ããåçãæå¹æ§ã»å®å
šæ§ç)ãå¿
èŠã ð
æ°åã³ãã
ããã¯è¯ããããããªãã
éžã¹ãã®ã¯è¯ããã
ããã ãã¯ã¯ãã³èªäœã®æ°ã足ããªãã£ãŠçŸç¶ã®ãªãçš®é¡ãéžæåºæ¥ãã£ãŠãããªäœè£ãããã®ããªïŒ
éã«éžæã«ããããšã«ãã£ãŠä»®ã«äœããã£ãæã¯ãããéžãã å人ã®ããã«ãããã®ããªãšåãã£ãŠããŸããã ãã©
éã«éžæã«ããããšã«ãã£ãŠä»®ã«äœããã£ãæã¯ãããéžãã å人ã®ããã«ãããã®ããªãšåãã£ãŠããŸããã ãã©
ãããéžã¹ãªããªããŠã©ãããšæããšäº¬å€§ã®å®®æ²¢ããã¯èšã£ãŠãããæãæŽãææ¥å»ã®äººã¯ãè¡æãã ãšèšãã
å人çã«ã¯èªåã®äœã®äžã«å ¥ãããã®ã®éžææš©ãå ã ç¡ãã»ããè¡æã ãšæã
å人çã«ã¯èªåã®äœã®äžã«å ¥ãããã®ã®éžææš©ãå ã ç¡ãã»ããè¡æã ãšæã
ã¯ã¯ãã³ã®éžæ( ^Ï^ )w
æ¶è²»è ã¯ã¯ã¯ãã³ãéžæããŠãã ããã ã£ãŠwãããŸã§æ¥ãã( á·ã ᷠ)
æ¶è²»è ã¯ã¯ã¯ãã³ãéžæããŠãã ããã ã£ãŠwãããŸã§æ¥ãã( á·ã ᷠ)
ãã³ããã¯ã¯ãã³ã ãã¡ã€ã¶ãŒã»ã¢ãã«ãã»ã¢ã¹ãã©ãŒãã« éžæå¯èœã« æ¥çš®äŒå Žããšçš®é¡åã
12 ãã¥ãŒããŒãã«ã®åç¡ããã
ã¢ã€ãã«ã®æ¡æäŒãããã¢ã¹ãã©ã¡ããäžäººæ°ã ããª
ïŒïŒäœåŠãŸã§ãæ»èµ°è·¯ã®ã¢ã¹ãã©ã¡ãã
12 ãã¥ãŒããŒãã«ã®åç¡ããã
ã¢ã€ãã«ã®æ¡æäŒãããã¢ã¹ãã©ã¡ããäžäººæ°ã ããª
ïŒïŒäœåŠãŸã§ãæ»èµ°è·¯ã®ã¢ã¹ãã©ã¡ãã
ã¢ã€ãã«ã®æ¡æäŒã¿ããã«ãªãã®ããª
ãã£ãã¯ã¢ãã«ãã§ãé¡ãããŸã
ãã€ãŸã?ã
ãåŸã§æå¹æ§ãåé¡ã«ãªãã®ã ããæ¯èŒã§ããããã«æ²»éšãšåãããã«å¹æã®ãªãæ¯èŒå¯Ÿç §è¬ãšããŠäžžå±±ã¯ã¯ãã³æãšããã
ãåŸã§æå¹æ§ãåé¡ã«ãªãã®ã ããæ¯èŒã§ããããã«æ²»éšãšåãããã«å¹æã®ãªãæ¯èŒå¯Ÿç §è¬ãšããŠäžžå±±ã¯ã¯ãã³æãšããã
ã»ãŒ / æ°åã³ãã
ããŒãé©ãã
ã¢ã€ãã«ã®æ¡æäŒããªïŒ
å°æ¥çã«ïœ±ïŸïœŒïŸïœªïœœïŸïœžïŸïŸäŒå Žãäœãã®âïžèª°ãè¡ããžãããããã©ð€£
äœããâŒïžããžã§ãããâŒïž
ãã¿ããããïžðžðð¥ððð
ãã¿ããããïžðžðð¥ððð
ãŸã äŸçµŠãã§ãããã©ãããšãã段éã§ããèšã£ãŠå€§äžå€«ãïŒ ãšãããããã©ãéžãã§ã倧äžå€«ã ãšã¯æãããã©ãã
â
â
ãèŠåŒµãå¡ãããã£ãšãããªããããïŒïŒïŒïŒããã®åœã¯åãåœã§ããå¿è«ç®èã ãâŠéžæåãæãã¬çžã®ç®ç®çš=å°æ¹è¡è²¡æ¿èª¿æ»äŒç調æ»:æ¿ä»€åžçèš109ã®4å²43å£äœãâæªå®ââ調æŽäžââã¯ã¯ãã³äŸçµŠã«é¢ããåœããã®æ
å ±äžè¶³çã§å
ãèŠéãã¬å®æ
æµ®ã圫ã!ã¯ã¯ãã³éžæå¯èœã«ãšã¯âª
倧ãã¥ãŒã¹ãããã§ãããã
ã
倧颚åæ·æ¡ããŠå€§äžå€«ãïŒæ²³éãããããªã€ããã¯ãªãããšãèšãåºãããã
æ¿åºã¯èªãã®éŠãçµããããŒãã«ãäžããã
å ¬èšããããšã¯ãé»ã£ãŠåæ ã«ã¯åºæ¥ããã
倧颚åæ·æ¡ããŠå€§äžå€«ãïŒæ²³éãããããªã€ããã¯ãªãããšãèšãåºãããã
æ¿åºã¯èªãã®éŠãçµããããŒãã«ãäžããã
å ¬èšããããšã¯ãé»ã£ãŠåæ ã«ã¯åºæ¥ããã
ããç¹å®ã®ã¯ã¯ãã³ã ãåžæè
ãå°ãªããŠäœã£ãŠããŸã£ããã©ããããã ããïŒã¯ã¯ãã³ã®å¹èœãå¯åå¿ã«å¯Ÿããæ
å ±åŒ±è
ã«æ¥çš®ãããã®ããªïŒ
ãã°ãã®æ¥ãâŠâŠ ïŒ
ã¯ã¯ãã³é¢é£ã§
ã¯ã¯ãã³ãéžæå¯èœã«ãããšèšã
æ¿åºåŽã
ããã¯æäœéå®ã£ãŠæ¬²ããã
ã¯ã¯ãã³ãéžæå¯èœã«ãããšèšã
æ¿åºåŽã
ããã¯æäœéå®ã£ãŠæ¬²ããã
ãŸã ãŸã ãã€æ¥çš®åºæ¥ããããããªãã®ã«âŠå®ããè²·ãåã«åœãŠãæã®äœ¿ãéèããŠãæèãšåã
å°æ¹ã¯éå£æ¥çš®äŒå ŽéãããŠåžæã¯ã¯ãã³ã¯çé1æéã®é æ¹ãšãã«ãªããã
å°æ¹ã¯éå£æ¥çš®äŒå ŽéãããŠåžæã¯ã¯ãã³ã¯çé1æéã®é æ¹ãšãã«ãªããã
ã³ããã¯ã¯ãã³ã®çš®é¡ãæ¥çš®äŒå Žããšã«èªãéžæå¯èœã« å°æè£äœå®
ãã€æãŠãããããããã®ã«éžã¹ãŸãèšãããŠã
ã¡ãŒã«ãŒããšã®å¯äœçšã®çµ±èšãšãã¯å ¬è¡šããŠãããªããã ããã
ããã£ãŠäžå®ãç œãã ãããã
ãã€æãŠãããããããã®ã«éžã¹ãŸãèšãããŠã
ã¡ãŒã«ãŒããšã®å¯äœçšã®çµ±èšãšãã¯å ¬è¡šããŠãããªããã ããã
ããã£ãŠäžå®ãç œãã ãããã
ãããªããšèšã£ã¡ãã£ãŠããã®ïŒ
åºæ¥ãã®ïŒïŒ
ã æ¥çš®äŒå Žããšçš®é¡åãâå°æè£äœå®
åºæ¥ãã®ïŒïŒ
ã æ¥çš®äŒå Žããšçš®é¡åãâå°æè£äœå®
åœæ°ãã©ã®çš®é¡ã®ã¯ã¯ãã³ãæ¥çš®ãããèªãéžæã§ããããã«ããèããæããã«ãããèšäºåç
§âââ
ãã ç¡é§ãçã¿åºãã ããããªãããéžã°ããªãã£ããã®ã¯æšãŠãã®ãïŒ
ã
éœåžéšã ããããªãã ãããª
ãéçå°ãé¢å³¶ã¯ç¡çããªããŠãããšããèšããªããå°æåâŠ
éœåžéšã ããããªãã ãããª
ãéçå°ãé¢å³¶ã¯ç¡çããªããŠãããšããèšããªããå°æåâŠ
âæ°åã³ãããŠã€ã«ã¹ã¯ã¯ãã³æ
åœã®å°æå²æ倧è£è£äœå®ã¯28æ¥ã®ããžãã¬ãçªçµã§ãåœæ°ãã©ã®çš®é¡ã®ã¯ã¯ãã³ãæ¥çš®ãããèªãéžæã§ããããã«ããèããæããã«ãããâ 人æ°äžäººæ°ãåãããããªã / âæ°åã³ãã
ããã€çã£ãŠããðŠ
ã©ãã«ãããªã¯ã¯ãã³ãã£ãŠããã€ããæååºæ¥ããïŒïŒïŒð³ð³ð³
ã©ãã«ãããªã¯ã¯ãã³ãã£ãŠããã€ããæååºæ¥ããïŒïŒïŒð³ð³ð³
ã¢ã¹ãã©ãŒãã«ã¯ã¯ãã³ãéžã¶äººã¯çç¡ã
åšåº«ã®å±±ã«ãªãåã«ãäžæ¢ãããäŸçµŠéãéçãŸã§äžããæ¹ãããã
ã¢ãã«ããšãã¡ã€ã¶ãŒãªãç¥å床ã§ãã¡ã€ã¶ãŒã«åŸãã ããã
åšåº«ã®å±±ã«ãªãåã«ãäžæ¢ãããäŸçµŠéãéçãŸã§äžããæ¹ãããã
ã¢ãã«ããšãã¡ã€ã¶ãŒãªãç¥å床ã§ãã¡ã€ã¶ãŒã«åŸãã ããã
æã€ã¯ã¯ãã³ãéžæããäœè£ããã®ãïŒ
ã³ããã¯ã¯ãã³ã®çš®é¡ãæ¥çš®äŒå Žããšã«èªãéžæå¯èœã« å°æè£äœå® ãæ¥çš®äŒå Žããšã«æã€ã¯ã¯ãã³ïŒã®çš®é¡ïŒã決ããŠãããããã¯å
¬è¡šãããã®ã§ãäŒå Žãéžã¹ã°æã€ã¯ã¯ãã³ãéžã¶ããšãã§ããã
ã¢ããªããŸãšãã«äœããªãã®ã«åºæ¥ãŸãããïŒ
ã¢ããªããŸãšãã«äœããªãã®ã«åºæ¥ãŸãããïŒ
ã©ã®ã¯ã¯ãã³ãéžã¹ã°ããããªããŠã倧åã®æ¥æ¬äººã«ã¯åãããŸãããè±èªãèªããªãæ¥æ¬äººã倧åãªã®ã§ãæ²»éšçµæãç解åºæ¥ãŸãããéžææ§ã¯ç¡æå³ã ãããããã»ããç¡é£ã
çŸå Žãæ··ä¹±ããããªãã ãããã®ããšã¯åãã£ãäžã§ã®çºèšãªãã ãããïŒ
ååãäžãã£ãŠãäŒç€Ÿã®ååã
ã©ããããã§ããªã
ã©ããããã§ããªã
éžæå¯èœãªãã°ã§ããã°ãã¡ã€ã¶ãŒã®ãã€æã¡ãããªã
ããã»ã»ã»ã
ä»ã ãšãã¡ã€ã¶ãŒã«éäžããããããªãïŒ
俺ã¯åœç£ã¯ã¯ãã³ã®æ¡æã¬ãŒã³ã«äžŠã³ãããããã©ã
ãŸã ãŸã ã§ããïŒïŒç¬¬3çžã¯ãïŒ
ä»ã ãšãã¡ã€ã¶ãŒã«éäžããããããªãïŒ
俺ã¯åœç£ã¯ã¯ãã³ã®æ¡æã¬ãŒã³ã«äžŠã³ãããããã©ã
ãŸã ãŸã ã§ããïŒïŒç¬¬3çžã¯ãïŒ
ã¢ãã¬ã³ã¯ïŒ
ã³ããã¯ã¯ãã³ã®çš®é¡ãæ¥çš®äŒå Žããšã«èªãéžæå¯èœã« å°æè£äœå® âPRâ
ã©ãŒããŸã çŸå Žã¯
ãèããŠç¡ãããã£ã
ãªãã ãããªã
ãèããŠç¡ãããã£ã
ãªãã ãããªã
ãããmRNAã¯ã¯ãã³ã®ãã¡ã€ã¶ãŒãã¢ãã«ãã§ãããããããããªããçŸç¶ã®æ
å ±ã ãã§èšãã°ãã¢ã¹ãã©ãŒãã«ã®ãã¯ã¿ãŒã¯ã¯ãã³ãéžæããåœæ°ãããŸããã
å°æ¹ã§äŒå Žã«éžæã®äœå°ãªããã§ãããã§ãããïŒ
ã¯ã¯ãã³ éžæå¯èœã«
ãæ¥çš®äŒå Žããšã«æã€ã¯ã¯ãã³ã決ãããå ¬è¡šãããã®ã§äŒå Žãéžã¹ã°æã€ã¯ã¯ãã³ãéžã¶ããšãã§ããã
é«éœ¢è ã¯ç±³è£œè¬å€§æãã¡ã€ã¶ãŒç€Ÿè£œã®ã¯ã¯ãã³ã
äžè¬åãã¯è±è£œè¬å€§æã¢ã¹ãã©ãŒãã«ãšç±³ãã€ãªå»è¬åäŒæ¥ã¢ãã«ããããäŸçµŠãåããäºå®ã
ãæ¥çš®äŒå Žããšã«æã€ã¯ã¯ãã³ã決ãããå ¬è¡šãããã®ã§äŒå Žãéžã¹ã°æã€ã¯ã¯ãã³ãéžã¶ããšãã§ããã
é«éœ¢è ã¯ç±³è£œè¬å€§æãã¡ã€ã¶ãŒç€Ÿè£œã®ã¯ã¯ãã³ã
äžè¬åãã¯è±è£œè¬å€§æã¢ã¹ãã©ãŒãã«ãšç±³ãã€ãªå»è¬åäŒæ¥ã¢ãã«ããããäŸçµŠãåããäºå®ã
å
åã«äŸçµŠåºæ¥ãªãã®ã«éŠ¬é¹¿ãªäºèšãåºããªããäžå»ãæ©ãæ¥çš®åºæ¥ãäºãéèŠïŒ
ãããããããªäœè£ãåºãã»ã©ã¯ã¯ãã³æ¥æ¬ã«å
¥ã£ãŠããã®ããã
â(ÂŽÐŽ`)â
ãããã§è§£æ±ºãããªãç§ã¯AZã§ãè¯ããèã¯éšåãçµããäºãäžèº«ãå¹ãããå¹ããŸããé¢ä¿ãªããããšåå¿ã¯ç³ããŠããããã
ãããŸããäºçŽãšãåå¥æ¥çš®ãžã®åå ã®é£æ床ããããŠãããã
çš®é¡éžã¹ãªããšã¢ããŠã³ã¹ãç¶ããŠããã®ã«ããªãä»å€ããã®ïŒïŒæ¯ãåãããããŠèå¿ã®æ¥çš®æºåã劚ããŠããŸããèªæ²»äœå»åž«äŒãšåè°ããŠããã®çºèšããã ãããïŒ
çš®é¡éžã¹ãªããšã¢ããŠã³ã¹ãç¶ããŠããã®ã«ããªãä»å€ããã®ïŒïŒæ¯ãåãããããŠèå¿ã®æ¥çš®æºåã劚ããŠããŸããèªæ²»äœå»åž«äŒãšåè°ããŠããã®çºèšããã ãããïŒ
æå ±âŠãšèšããããšããã ãããã€æãŠãããåãããªãã®ã«ãéžã¹ãŸãããšèšãã®ã¯ãã€ããå¯åå¿åºãŠããéžãã ã®ã¢ã³ã¿ã ããèªå·±è²¬ä»»ããšçªãæŸããããã§æããª ïŒ @ jijicom
ãããããã¯ã¯ãã³ã®ç¢ºä¿ã«å€±æããŠããæ¥æ¬ã«ã¯ãå
ããªéã®ã¯ã¯ãã³ããå
¥è·ã§ããŠããããå»çåŸäºè
ã®æ¥çš®ãçµãã£ãŠããªããéžã¹ãã©ããããæ¥çš®ã§ããªãç¶æ³ããã€ãŸã§ç¶ãã®ãã
æå¹æ§
ãã¡ã€ã¶ãŒ 95%ðºðž
ã¢ãã«ã 94.5%ðºðž
ã¢ã¹ãã©ãŒãã« 79%ð¬ð§
Johnson &Johnson 72ïŒ ðºðž
ã·ãããã¯83ïŒ ðšð³
ãã¡ã€ã¶ãŒ 95%ðºðž
ã¢ãã«ã 94.5%ðºðž
ã¢ã¹ãã©ãŒãã« 79%ð¬ð§
Johnson &Johnson 72ïŒ ðºðž
ã·ãããã¯83ïŒ ðšð³
éžã¹ããªãã»ãšãã©ã®äººããã¡ã€ã¶ãŒã§ã¢ãã«ããªãææ
¢ãããšããããšã«ãªãã®ã§ã¯ãªãã ããããAZãç©æ¥µçã«éžã¶äººããããšã¯èãã«ããã
ãããéžæã®èªç±ïŒèªå·±è²¬ä»»ã®å¢å ããª( ÂŽãŒïœ)y-~~ã
ãã€ã©ãã ãå
¥ã£ãŠããããåãããªãã®ã«ç¡è²¬ãªããšãèšããªã
ã¡ãŒã«ãŒã«ãã£ãŠã¯ã¯ãã³ãæºåãããã©ãäœãããŠããŸããšãåºãŠããªãïŒ1åç®ãš2åç®ã¯åäžã¡ãŒã«ãŒã®ã¯ã¯ãã³ãæããªããšãããªããšãããã®ããªïŒ
ãã®éžæå¶åºŠã¯ãããæ¹ãããã
äœãèµ·ããããæ³ååããªãã®ãïŒ
ã³ããã¯ã¯ãã³ã®çš®é¡ãæ¥çš®äŒå Žããšã«èªãéžæå¯èœã« å°æè£äœå®
äœãèµ·ããããæ³ååããªãã®ãïŒ
ã³ããã¯ã¯ãã³ã®çš®é¡ãæ¥çš®äŒå Žããšã«èªãéžæå¯èœã« å°æè£äœå®
äžåœã¯ã¯ãã³ããã·ã¢ã®ã¹ããŒããã¯ãéžæè¢ã«å
¥ããŠããïœã
ãããªããšããããçŸå Žãæ··ä¹±ããŸããããã
ðç§ãã¢ã³ãžã§ã¹ããããä»ã¯ã€ã€ãã¢ã³ãžã§ã¹ä»¥å€ã¯æ¥çš®ããŸããã
âªã¯ã¯ãã³ éžæã® èªç±
ã¢ããã³
ãããããã
ãããããã
âš
ã¢ããã³
ãããããã
ãããããã
âš
<åè>ãã¡ããã¯ã¯ãã³æ¥çš®ãå§ãŸã£ãŠããã®çãåããæ¡ä»¶
28æ¥ã®ããžãã¬ãçªçµã§ãåœæ°ãã©ã®çš®é¡ã®ã¯ã¯ãã³ãæ¥çš®ãããèªãéžæã§ããããã«ããèããæããã«ããã
æ°åã³ãã
28æ¥ã®ããžãã¬ãçªçµã§ãåœæ°ãã©ã®çš®é¡ã®ã¯ã¯ãã³ãæ¥çš®ãããèªãéžæã§ããããã«ããèããæããã«ããã
æ°åã³ãã
ããããããåœå
çç£ã®ã¯ã¯ãã³ãäžå»ãæ©ãçç£ããŠãæ¿èªãããäºãæ¥åã ãšæãã
ãã¡ã€ã¶ãŒäžæã«ãªããšæããã©âŠ
ã¢ã¹ãã©ãŒãã«ããªã¯ã¿
ããã ãšç¹å®ã®è£œåã«äººæ°ãéäžãããã ãã©ãã©ã®ã¯ã¯ãã³ã§ããã人ã¯æ©ãã¯ã¯ãã³ãæãŠãããã«ãªãã®ããª? ãŸããšãããã¯ã¯ãã³ãå®å®äŸçµŠã§ããããã«ããã®ãå
ã§ãããïŒ ã¯ã¯ãã³ãéžæå¯èœã« æ¥çš®äŒå Žããšçš®é¡åãâå°æè£äœå®
ã©ã®æçãå«ãªã®ããããªãã®ãèªåã«ã¯å¿
èŠãªãã®ãæã¡ãã人ã ãã©ãããªã®( ÂŽ_ã`)
ã¯ã¯ãã³ãéžæå¯èœã« æ¥çš®äŒå Žããšçš®é¡åãâå°æè£äœå®
ã¯ã¯ãã³ãéžæå¯èœã« æ¥çš®äŒå Žããšçš®é¡åãâå°æè£äœå®
3çš®ã®ã¯ã¯ãã³å
šéšã®ã
ïœïŒRNAãã·ãã·
解åå ·åã¯ã·ã£ãŒãããç¶ã§
ãé¡ãããŸã
ïœïŒRNAãã·ãã·
解åå ·åã¯ã·ã£ãŒãããç¶ã§
ãé¡ãããŸã
æ瀟ã®ãã€ã売ãæ®ãã®ãç®ã«èŠããŠãããã§ããã
æžå¿µãé
æ
®ããŠã®æ¿çã¯è¯ããšæããã人æ°ã¯åãã¯ãã§ããã蟌ã¿ã§èšç»ããŠãããã©ãã
ã¯ã¯ãã³ãéžæå¯èœã« æ¥çš®äŒå Žããšçš®é¡åãâå°æè£äœå®
ã¯ã¯ãã³ãéžæå¯èœã« æ¥çš®äŒå Žããšçš®é¡åãâå°æè£äœå®
ãæ°åã³ããã¯ã¯ãã³ãçš®é¡ã®éžæãå¯èœã«ã
æ°åã³ãããŠã€ã«ã¹ã¯ã¯ãã³æ åœã®å°æ倧è£è£äœå®ã¯28æ¥ã®ããžãã¬ãçªçµã§ãåœæ°ãã©ã®çš®é¡ã®ã¯ã¯ãã³ãæ¥çš®ãããèªãéžæã§ããããã«ããèããæããã«ãã
å¯åå¿ãªã©å人ã®äºæ ã§ãã¯ã¯ãã³ã®éžæãå¯èœã«ð
æ°åã³ãããŠã€ã«ã¹ã¯ã¯ãã³æ åœã®å°æ倧è£è£äœå®ã¯28æ¥ã®ããžãã¬ãçªçµã§ãåœæ°ãã©ã®çš®é¡ã®ã¯ã¯ãã³ãæ¥çš®ãããèªãéžæã§ããããã«ããèããæããã«ãã
å¯åå¿ãªã©å人ã®äºæ ã§ãã¯ã¯ãã³ã®éžæãå¯èœã«ð
æåã®é«éœ¢è
åãã¯ã¯ãã³ã¯ãã¡ã€ã¶ãŒç€Ÿè£œãªãã ãããã¯äž¡èŠªã«ã¯ã¡ãã£ãšå®å¿ã
ãããããçŸå Žå€§æ··ä¹±ééããªãã ãïŒïŒ
åã§ããïŒïŒããš12æ¥ããé«éœ¢è ã®æ¥çš®éå§ïŒãŸã è·å Žã§å»çåŸäºè æ¥çš®éå§ããŠãªããã©ïŒïŒ
åã§ããïŒïŒããš12æ¥ããé«éœ¢è ã®æ¥çš®éå§ïŒãŸã è·å Žã§å»çåŸäºè æ¥çš®éå§ããŠãªããã©ïŒïŒ
ç¹å®ã®çš®é¡ã«åžæãåã£ãŠãæ¥çš®è
æ°ã®æžå°ãšã¯ã¯ãã³äœããäž¡æ¹çããŠããŸãã®ã§ã¯ãšæžå¿µãããã
ãããªãã°ãã©ã®ã¯ã¯ãã³ãæå¹æ§ãšå®å šæ§ãæ ä¿ãããŠããããšã®ä»ã«ã幎代ãå¥åº·ç¶æ ã«ããæšå¥šåãããã£ãŠããšæãã
ã¯ã¯ãã³ãéžæå¯èœã« æ¥çš®äŒå Žããšçš®é¡åã
ãããªãã°ãã©ã®ã¯ã¯ãã³ãæå¹æ§ãšå®å šæ§ãæ ä¿ãããŠããããšã®ä»ã«ã幎代ãå¥åº·ç¶æ ã«ããæšå¥šåãããã£ãŠããšæãã
ã¯ã¯ãã³ãéžæå¯èœã« æ¥çš®äŒå Žããšçš®é¡åã
æäºéä¿¡ã¯ãããªèŽ
æ²¢ãªããšãã§ããç¶æ³ã«æã¡èŸŒããã»ã©ãããŸã§ã¹ããŒãã£ã«ã§ãããšæ¬æ°ã§æã£ãŠããã®ïŒ
ã¯ã¯ãã³ãéžæå¯èœã« æ¥çš®äŒå Žããšçš®é¡åãâå°æè£äœå®
BioNTech Pfizer
Moderna
AstraZeneca
æå€ã«é«éœ¢è ã¯mRNAã¯ã¯ãã³ã«å¯ŸããŠå¿é¿æããã£ããããã ãããïŒAstraZenecaã¯åœç£ã ãïŒ
Novavaxã¯éåžžã®å·èµåº«ã§é·æéä¿ã€ãæ°è»œã«è¿ãã®ã¯ãªããã¯ã§åããããã楜ãã
Moderna
AstraZeneca
æå€ã«é«éœ¢è ã¯mRNAã¯ã¯ãã³ã«å¯ŸããŠå¿é¿æããã£ããããã ãããïŒAstraZenecaã¯åœç£ã ãïŒ
Novavaxã¯éåžžã®å·èµåº«ã§é·æéä¿ã€ãæ°è»œã«è¿ãã®ã¯ãªããã¯ã§åããããã楜ãã
çŸå Žãæ··ä¹±ããã ããæ¬åœã«ç¡è²¬ä»»æ¥µãŸããªãã
ããã¯è¿·ãã2åç®ããã€æãŠããããããªãããã1åã§æžãæ¹ãããæ°ãããããäžæãããšçãééã§2åæã£ãŠå®å
šã«ãŠã€ã«ã¹ãé²ããããããã
æ°åã³ãã
æ°åã³ãã
ã¯ã¯ãã³ã®çš®é¡æã€äººãéžæå¯èœãªããã«ããããåã¢ããªã«æ ªã«å¯ŸããŠã¯å¹æãäœããšããããŒã¿ãåºãŠãã¢ã¹ãã©ãŒãã«ã®ã¯ã¯ãã³ãã¿ããªé¿ããŠãã¡ã€ã¶ãŒã«æ®ºå°ããããåœç¶ã¯ã¯ãã³è¶³ããªããªãïŒäœã£ãã¢ã¹ãã©ãŒãã«ã©ããããã§ããïŒ
ãã¬ãã§ã®çºèšãªã®ã... äœããã©ã°ãç«ã£ãæ°ããããª...
ãããªäºãèšã£ãŠãå Žåããããã ã
çŸå Žãæ··ä¹±ãããå å¶
éæ»æŽè¿